This Company's Cardiac Monitor Has Caught the Eye of Johnson & Johnson and Stanford

Future Cardia’s device

This post contains sponsored advertising content. The content that follows is for informational purposes only and not intended to be investing advice.

Future Cardia says it is set to disrupt the cardiac monitoring technology market with a product the company believes is best-in-class for saving heart patients’ lives.

Cardiac monitors are giving patients a new lease on life — especially those who stand a greater risk of suffering complications like heart palpitation, which can be a life-threatening, severe medical issue. Heart palpitation occurs when the heart skips a beat, flutters rapidly, or beats abnormally, resulting in a situation called arrhythmia.

Technology Saving Lives

To attempt to avert these life-threatening circumstances, remote patient monitoring (RPM) through implantable and wearable devices is helping patients and doctors detect and offer timely treatment.

From wearables released by Apple Inc. AAPL, Garmin Ltd. GRMN, Samsung Electronics Co. Ltd. (KRX: 005930), and OMRON Corp. 6645 to invasive heart procedure devices like CardioMEMS HF System by Abbott Laboratories ABT, they all offer different features.

CardioMEMS, for example, and other notable devices require a sensor implant inside the heart or around the heart (pulmonary artery) in a catheter laboratory procedure that can end up being expensive, complex, and is not the ideal solution for all patients.

Future Cardia says that it is solving these shortcomings with its device. The device is delivered through a 2-minute office procedure via a small incision under the skin and covered with an adhesive bandage with no follow-ups needed. Each device provides comprehensive data and analysis to doctors and yields billions of data points, allowing healthcare providers to compare trending changes for continuous cardiac monitoring over 2 to 3 years.

It is equipped with an acoustic sensor to listen to heart and lung sounds, an electrocardiogram (ECG) for heart rhythms, and a 3-axis accelerometer that records activity, posture, and body orientation. All the data is securely sent to the phone and a cloud-based artificial intelligence (AI) for the cardiologist to monitor heart failure remotely.

Jaeson Bang, founder, and CEO of Future Cardia

Future Cardia states that this innovation has been made possible by a passionate and dedicated team of cardiologists, scientists, engineers, and entrepreneurs with more than 180 years of combined experience in heart failure and cardiac arrhythmias.

At the helm of affairs is Jaeson Bang, who founded the company in May 2019 after nearly 18 years years in Clinical, Technology and business operations with Medtronic (MDT, fortune 500) and other notable silicon valley startups. 

While at EBR, Bang worked cross-functionally with engineers on device development as well as leading a national team of therapy development managers and field clinician engineers, in US and Europe. 

Before that, he spent time consulting the business and clinical operations team at Keystone Heart Ltd., a venture-backed Israeli medical technology company. Throughout his career, Bang has worked at startups that operate at the intersection of medicine, technology, and business. 

Bang graduated from Northwestern University — Kellogg School of Management with his MBA in 2015. Future Cardia says its team and advisors include:

• Professor Frits Prinzen, cardiac hemodynamics scientist with expertise in heart failure and cardiac mechanics.
• Dr. Toshi Okabe, a cardiologist specializing in cardiac arrhythmias and electrophysiology, currently practicing at Ohio State University.

Read more about the team here.

Partners

Notable among the company’s partners are Johnson & Johnson Innovation — JLABS (JLABS), Stanford StartX program, and Texas Medical Center.

Johnson & Johnson (JLABS)

JLABS is a global network of open innovation ecosystems enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer, and healthtech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. 

JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections and other benefits. 

Beyond its growing network of incubation capabilities worldwide, JLABS is part of the larger Johnson & Johnson Innovation family of companies.

What that means for young companies like Future Cardia is that JLABS can provide access to all the elements companies need to develop their science and try to position them for success.

Stanford Startx Program

The Stanford StartX program is a collection of more than 1,800 serial entrepreneurs, industry experts, tenured Stanford professors, and more than 700 well-funded growth-stage startups. 

StartX believes entrepreneurs can achieve more as a group than as individuals. As a community, the goal is to find creative ways to collaborate with companies like Future Cardia (formerly known as Oracle Health)to have a long-term positive impact on the world.

StartX is known for having 10 unicorn startups in 12 years. Highest in any startup ecosystem in the world. 

You should read the Offering Circular (link) and Risks (link) related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA (link)/SIPC (link). This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

This post contains sponsored advertising content. The content that follows is for informational purposes only and not intended to be investing advice.